Bio-Techne Corp

More Details of Bio-Techne Corp Company

Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.

Company Info

Company codeTECH

Company nameBio-Techne Corp

IPO dateFeb 09, 1989

Founded at1981

CEOMr. Kim Kelderman

Number of employees3100

Security typeOrdinary Share

Fiscal year-endFeb 09

Address614 Mckinley Pl N E

CityMINNEAPOLIS

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code55413

Phone16123798854

Websitehttps://www.bio-techne.com/

Company codeTECH

IPO dateFeb 09, 1989

Founded at1981

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. John L. Higgins

Independent Director

48.20K

+3.13%

Mr. Robert V. (Bob) Baumgartner, CPA

Independent Chairman of the Board

44.86K

+3.37%

Dr. Roeland Nusse, Ph.D.

Independent Director

44.56K

+3.39%

Mr. Kim Kelderman

President, Chief Executive Officer, Chief Operating Officer, Director

37.51K

--

Dr. Joseph D. (Joe) Keegan, Ph.D.

Independent Director

13.77K

+11.88%

Dr. Rupert J. Vessey, Ph.D.

Independent Director

9.35K

+18.54%

Ms. Julie L. Bushman

Independent Director

7.13K

+25.77%

Mr. Shane Bohnen

Senior Vice President, General Counsel, Corporate Secretary

3.19K

+90.01%

Dr. Matthew F. Mcmanus

President - Diagnostics and Genomics Segment

2.98K

--

Dr. Judith V. Klimovsky, M.D.

Independent Director

2.14K

+215.00%

Name

Name/Position

Position

Shareholding

Change

Mr. John L. Higgins

Independent Director

48.20K

+3.13%

Mr. Robert V. (Bob) Baumgartner, CPA

Independent Chairman of the Board

44.86K

+3.37%

Dr. Roeland Nusse, Ph.D.

Independent Director

44.56K

+3.39%

Mr. Kim Kelderman

President, Chief Executive Officer, Chief Operating Officer, Director

37.51K

--

Dr. Joseph D. (Joe) Keegan, Ph.D.

Independent Director

13.77K

+11.88%

Dr. Rupert J. Vessey, Ph.D.

Independent Director

9.35K

+18.54%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Consumables

230.72M

77.67%

Instruments

30.87M

10.39%

Service

27.35M

9.21%

Royalty

8.10M

2.73%

By RegionUSD

Name

Revenue

Proportion

United States

159.91M

53.83%

EMEA, excluding U.K

70.39M

23.70%

Greater China

24.75M

8.33%

APAC, excluding Greater China

19.01M

6.40%

United Kingdom

13.24M

4.46%

Rest of World

9.73M

3.27%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Consumables

230.72M

77.67%

Instruments

30.87M

10.39%

Service

27.35M

9.21%

Royalty

8.10M

2.73%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.72%

T. Rowe Price Associates, Inc.

6.60%

BlackRock Institutional Trust Company, N.A.

5.85%

State Street Global Advisors (US)

4.09%

Baron Capital Management, Inc.

2.62%

Other

69.12%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.72%

T. Rowe Price Associates, Inc.

6.60%

BlackRock Institutional Trust Company, N.A.

5.85%

State Street Global Advisors (US)

4.09%

Baron Capital Management, Inc.

2.62%

Other

69.12%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

47.40%

Investment Advisor

44.16%

Hedge Fund

2.25%

Bank and Trust

2.16%

Pension Fund

1.88%

Research Firm

1.54%

Sovereign Wealth Fund

1.27%

Individual Investor

1.04%

Insurance Company

0.23%

Institutional Shareholding

Update time: Mon, Jan 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

1193

162.20M

102.60%

-2.87M

2024Q4

1233

162.21M

102.61%

-6.39M

2024Q3

1205

159.40M

100.49%

-10.21M

2024Q2

1207

160.52M

101.86%

-12.24M

2024Q1

1216

162.56M

103.40%

-7.57M

2023Q4

1229

159.70M

100.98%

-3.97M

2023Q3

1217

156.41M

98.84%

-7.93M

2023Q2

1213

155.36M

98.68%

-4.04M

2023Q1

1206

153.08M

97.33%

-5.18M

2022Q4

1190

153.16M

97.57%

-6.72M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

18.52M

11.72%

+275.81K

+1.51%

Dec 31, 2024

T. Rowe Price Associates, Inc.

10.43M

6.6%

+1.23M

+13.34%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

9.25M

5.85%

+4.60K

+0.05%

Dec 31, 2024

State Street Global Advisors (US)

6.47M

4.09%

+76.69K

+1.20%

Dec 31, 2024

Baron Capital Management, Inc.

4.14M

2.62%

-308.56K

-6.94%

Dec 31, 2024

Geode Capital Management, L.L.C.

4.00M

2.53%

+98.66K

+2.53%

Dec 31, 2024

Neuberger Berman, LLC

3.58M

2.27%

+65.69K

+1.87%

Dec 31, 2024

D. F. Dent & Company, Inc.

3.20M

2.03%

-97.30K

-2.95%

Dec 31, 2024

Atlanta Capital Management Company, L.L.C.

2.95M

1.87%

-40.17K

-1.34%

Dec 31, 2024

Mairs and Power, Inc.

2.82M

1.78%

-24.98K

-0.88%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

Global X Genomics & Biotechnology ETF

4.16%

Invesco Biotechnology & Genome ETF

2.26%

Tema Monopolies and Oligopolies ETF

1.9%

VanEck Biotech ETF

1.79%

Hilton Small-MidCap Opportunity ETF

1.77%

Thrivent Small-Mid Cap ESG ETF

1.75%

iShares Health Innovation Active ETF

1.72%

Neuberger Berman Small-Mid Cap ETF

1.49%

Invesco S&P 500 Equal Weight Health Care ETF

1.27%

American Century Mid Cap Growth Impact ETF

0.98%

Global X Genomics & Biotechnology ETF

Proportion4.16%

Invesco Biotechnology & Genome ETF

Proportion2.26%

Tema Monopolies and Oligopolies ETF

Proportion1.9%

VanEck Biotech ETF

Proportion1.79%

Hilton Small-MidCap Opportunity ETF

Proportion1.77%

Thrivent Small-Mid Cap ESG ETF

Proportion1.75%

iShares Health Innovation Active ETF

Proportion1.72%

Neuberger Berman Small-Mid Cap ETF

Proportion1.49%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.27%

American Century Mid Cap Growth Impact ETF

Proportion0.98%

Dividend

A total of 249.41M USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 05, 2025

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025

Feb 17, 2025

Feb 28, 2025

Feb 14, 2025

Oct 30, 2024

TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024

Nov 11, 2024

Nov 22, 2024

Nov 08, 2024

Aug 07, 2024

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024

Aug 19, 2024

Aug 30, 2024

Aug 19, 2024

May 01, 2024

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024

May 13, 2024

May 24, 2024

May 10, 2024

Feb 01, 2024

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024

Feb 12, 2024

Feb 26, 2024

Feb 09, 2024

Oct 31, 2023

TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023

Nov 10, 2023

Nov 24, 2023

Nov 09, 2023

Aug 08, 2023

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 01, 2023

Aug 17, 2023

May 03, 2023

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023

May 15, 2023

May 26, 2023

May 12, 2023

Feb 02, 2023

TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023

Feb 13, 2023

Feb 27, 2023

Feb 10, 2023

Nov 01, 2022

TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022

Nov 14, 2022

Nov 28, 2022

Nov 10, 2022

Stock Split

Date

Type

Ratio

Nov 01, 2022

Split

1>4

Date

Type

Ratio

Nov 01, 2022

Split

1>4

50.850USD

Bio-Techne Corp

50.850

Overview

Company